Digest Network Come funziona
Network
/
Società
Re
Non verificato

Resolution Therapeutics

Di cosa scriviamo

BiologiaComunicazioneFarmaceuticaMediaSanità

7 comunicati stampa

Guarda tutti i comunicati
10/12/2024
Farmaceutica
Sanità
Biologia
Resolution Therapeutics Announces Presentation at Keystone Symposia on Fibrosis
Fonte
Resolution Therapeutics
Emittente
PR News Wire
1.00
0
19/11/2024
Farmaceutica
Sanità
Biologia
Resolution Therapeutics Announces Approval of Clinical Trial Application by AEMPS to Expand Phase 1/2 EMERALD Study of RTX001 into Spain
Fonte
Resolution Therapeutics
Emittente
PR News Wire
1.00
0
11/11/2024
Farmaceutica
Sanità
Resolution Therapeutics Announces New Clinical and Preclinical Data Showcasing Regenerative Macrophage Therapy at AASLD The Liver Meeting® 2024 to Support the Ongoing Phase 1/2 Study for RTX001 in End-Stage Liver Disease
Fonte
Resolution Therapeutics
Emittente
PR News Wire
1.00
0
03/10/2024
Farmaceutica
Sanità
Economia
Management
Organizzazione Aziendale
Biologia
Resolution Therapeutics Announces £63.5 Million Series B Financing and Chair Appointment
Fonte
Resolution Therapeutics
Emittente
PR News Wire
1.00
0
01/10/2024
Farmaceutica
Sanità
Finanza
Biologia
Resolution Therapeutics Announces Upcoming Presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2024
Fonte
Resolution Therapeutics
Emittente
PR News Wire
1.00
0
27/06/2024
Farmaceutica
Sanità
Biologia
Resolution Therapeutics Receives MHRA Approval to Commence Phase I/II EMERALD Study for Lead Candidate RTX001
Fonte
Resolution Therapeutics
Emittente
PR News Wire
1.00
0
13/06/2024
Farmaceutica
Sanità
Media
Comunicazione
Multimedialità
Editoria elettronica
Biologia
Resolution Therapeutics to Host Virtual R&D Webinar on Liver Disease with World Leading Hepatologist Arun Sanyal, M.D.
Fonte
Resolution Therapeutics
Emittente
PR News Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0